154 related articles for article (PubMed ID: 34847624)
21. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells.
Yang J; Pi C; Wang G
Biomed Pharmacother; 2018 Jul; 103():699-707. PubMed ID: 29680738
[TBL] [Abstract][Full Text] [Related]
22. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
23. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway.
Liu JS; Huo CY; Cao HH; Fan CL; Hu JY; Deng LJ; Lu ZB; Yang HY; Yu LZ; Mo ZX; Yu ZL
Phytomedicine; 2019 Aug; 61():152843. PubMed ID: 31039533
[TBL] [Abstract][Full Text] [Related]
24. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
25. CXC195 induces apoptosis and endoplastic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway.
Chen XL; Fu JP; Shi J; Wan P; Cao H; Tang ZM
Mol Med Rep; 2015 Dec; 12(6):8229-36. PubMed ID: 26496900
[TBL] [Abstract][Full Text] [Related]
26. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
27. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
28. Cucurbitacin I exhibits anticancer efficacy through induction of apoptosis and modulation of JAK/STAT3, MAPK/ERK, and AKT/mTOR signaling pathways in HepG2 cell line.
Üremiş N; Üremiş MM; Çiğremiş Y; Tosun E; Baysar A; Türköz Y
J Food Biochem; 2022 Oct; 46(10):e14333. PubMed ID: 35866877
[TBL] [Abstract][Full Text] [Related]
29. Molecular docking, anti-proliferative activity and induction of apoptosis in human liver cancer cells treated with androstane derivatives: Implication of PI3K/AKT/mTOR pathway.
Kattan SW; Nafie MS; Elmgeed GA; Alelwani W; Badar M; Tantawy MA
J Steroid Biochem Mol Biol; 2020 Apr; 198():105604. PubMed ID: 31982513
[TBL] [Abstract][Full Text] [Related]
30. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
31. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS
Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373
[TBL] [Abstract][Full Text] [Related]
32. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS
Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281
[TBL] [Abstract][Full Text] [Related]
33. Anti-liver cancer effect and the mechanism of arsenic sulfide in vitro and in vivo.
Wang S; Zhang C; Li Y; Li P; Zhang D; Li C
Cancer Chemother Pharmacol; 2019 Mar; 83(3):519-530. PubMed ID: 30542770
[TBL] [Abstract][Full Text] [Related]
34. An ethyl acetate fraction of Artemisia capillaris (ACE-63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma.
Jung KH; Rumman M; Yan H; Cheon MJ; Choi JG; Jin X; Park S; Oh MS; Hong SS
Phytother Res; 2018 Oct; 32(10):2034-2046. PubMed ID: 29972254
[TBL] [Abstract][Full Text] [Related]
35. [Baicalin induces ferroptosis in HepG2 cells by inhibiting ROS-mediated PI3K/Akt/FoxO3a signaling pathway].
Zhou JQ; Li HJ; Zeng YH; Chen HH; Liang WY; Zhang J; Ding FP
Zhongguo Zhong Yao Za Zhi; 2024 Mar; 49(5):1327-1334. PubMed ID: 38621980
[TBL] [Abstract][Full Text] [Related]
36. β-Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS-mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma.
Zhang G; He J; Ye X; Zhu J; Hu X; Shen M; Ma Y; Mao Z; Song H; Chen F
Cell Death Dis; 2019 Mar; 10(4):255. PubMed ID: 30874538
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human Prostate Cancer Cells.
Kim KY; Park KI; Kim SH; Yu SN; Park SG; Kim YW; Seo YK; Ma JY; Ahn SC
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524116
[TBL] [Abstract][Full Text] [Related]
38. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
[TBL] [Abstract][Full Text] [Related]
39. EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.
Pellegrino R; Calvisi DF; Neumann O; Kolluru V; Wesely J; Chen X; Wang C; Wuestefeld T; Ladu S; Elgohary N; Bermejo JL; Radlwimmer B; Zörnig M; Zender L; Dombrowski F; Evert M; Schirmacher P; Longerich T
Hepatology; 2014 May; 59(5):1886-99. PubMed ID: 24285179
[TBL] [Abstract][Full Text] [Related]
40. Apoptotic effect of compound K in hepatocellular carcinoma cells via inhibition of glycolysis and Akt/mTOR/c-Myc signaling.
Shin N; Lee HJ; Sim DY; Im E; Park JE; Park WY; Cho AR; Shim BS; Kim SH
Phytother Res; 2021 Jul; 35(7):3812-3820. PubMed ID: 33856720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
